Jing Zhu

Publications (2)4.29 Total impact

• Source

  Available from: PubMed Central

  Article: BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells.

  Jing Zhu, Li Sun, Sensen Lin, Renping Zhao, Liqiang Zhou, Dongdong Fang, Liang Chen, Jin Liu, Wenting Shi, Luyong Zhang, Shengtao Yuan
  [show abstract] [hide abstract]
  ABSTRACT: The role of B Lymphocyte Stimulator (BLyS) in the survival of malignant B cells and the maintenance of normal B cell development and homeostasis has been intensively studied in the literature. However, the influence of BLyS on breast cancer progression remains unclear. The study aimed to investigate the effect of hypoxia on BLyS regulation, cell migratory response to BLyS and the possible molecular mechanisms. In this study, we examined the role of BLyS in the migration of human breast cancer cells by transwell assay. We also explored whether BLyS and its receptors expressed in human breast cancer cell lines by immunofluorescence and Western Blotting. Then we detected the expression level of BLyS in both normoxic and hypoxic conditions by real time-PCR and Western Blotting. Pathways involved were confirmed by Western Blotting, immunofluorescence, transwell assay and luciferase assay. According to our study, the expression level of BlyS was increased in human breast cancer cell lines in hypoxic conditions. Up-regulation of this protein led to activation and nuclear translocation of NF-kappa B p65. We also found that the number of migrated cells was increased in the presence of BLyS and inhibition of phosphorylation of Akt attenuated the enhanced migratory response. It suggested that better understanding of BLyS, an immunopotentiator, may offer a potential therapeutic target for the treatment of human breast cancers. In addition, BLyS promoted breast cancer cells migration, underscoring the necessity of appropriate applications of immunopotentiators to cancer treatment.
  Journal of Experimental & Clinical Cancer Research 03/2012; 31:31. · 2.15 Impact Factor
• Article: Inhibition of angiogenic activity of hypoxic fibroblast cell line MRC-5 in vitro by topotecan.

  Liqiang Zhou, Li Sun, Sensen Lin, Dongdong Fang, Renping Zhao, Jing Zhu, Jin Liu, Liang Chen, Wenting Shi, Shengtao Yuan, Danni Zhu
  [show abstract] [hide abstract]
  ABSTRACT: Tumor stroma plays an important role in cancer development. Stromal fibroblasts often represent the majority of stromal cells within various types of human carcinomas, and they are competent to promote the growth of cancer cells and to enhance tumor angiogenesis. However, the effect of known anti-cancer drugs on stromal cells has not been thoroughly investigated. Topotecan (TPT) is a semi-synthetic analogue of camptothecin, and several studies have shown that TPT inhibited angiogenesis via its direct effect on vascular endothelial cells. Here, we studied the effect of TPT on pro-angiogenesis action of hypoxic fibroblasts (MRC-5 cells). Growth inhibition was analyzed by MTT assay, while transwell assay and tube formation assay were used to evaluate the inhibition by TPT of hypoxic MRC-5 cell angiogenic activity in vitro. ELISA and Western blot analysis were used to investigate the related mechanism. Pretreatment of MRC-5 with TPT remarkably attenuated the induction of migration and tube formation of HUVECs by conditioned medium from hypoxic MRC-5 cells. In addition, topotecan decreased hypoxia-induced VEGF production by MRC-5 cells. Moreover, topotecan inhibits HIF-1α and α-SMA protein expression in hypoxic MRC-5 cells. Our data suggest that TPT inhibits hypoxic fibroblast angiogenic activity via downregulation of HIF-1α and prevention of fibroblast differentiation to myofibroblast.
  Medical Oncology 11/2010; · 2.14 Impact Factor